Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of recombinant human thyrotropin for radioactive iodine remnant ablation in differentiated thyroid cancer
CTR20201190Phase 2Completed
- Sponsor
- Zelgen
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of thyrotropin alfa in well-differentiated thyroid cancer (WDTC), sponsored by Zelgen. Started Nov 2020; status: completed.
02
Drugs
thyrotropin alfa
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20201190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201190.